Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
“The strongest companies are built on the right foundations long before their moment arrives,” says CEO Jody AufrichtigNEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment ...